Purdue Pharma L.p.

Merck Sharp + Dohme Corp.

Andrew Kassick

Laykea Tafesse

Jinlong Jiang

Jeffrey Lockman

Sander G Mills

Jianming Bao

Iyassu Sebhat

Robert J DeVita

Ahmet Kekec

Dawit Tadesse

The application provides compounds of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, R, dash line a, dash line b, W, Z, X, and m are defined as set forth in the specification. The invention is also directed to use of the compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. In certain embodiments, the Compounds of the Invention are useful for treating pain. 

6,7-cyclicmorphinan derivatives and use thereof

The application is directed to compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, and Rare defined as set forth in the specification. The invention is also directed to use of compounds of Formula I to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

Substituted morphinans and the use thereof

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. 

Cyclic benzimidazole derivatives useful as anti-diabetic agents

The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.

Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists

Growing community of inventors

Scotch Plains, NJ, United States of America

Andrew Kassick